Subscribe To

Price Alert Latest News Economic Calendar News

VIVO / Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? Read More

Demo Live Account See Partner Details

Content Topics

The

Duckhorn

Portfolio

Inc

Napa

Meridian

Bioscience

vivo

Earnings

Revenues

Surpass

Estimates

Stock

VIVO

Posted: Feb 4 2022, 10:43

Author Name: Zacks Investment Research

VIVO News

By Investors Business Daily
November 17, 2022

Medical Devices Stock Pumps Up Buy Point With New Innovations

After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new bu

By InvestorPlace
July 7, 2022

Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement

VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The pos

By Seeking Alpha
July 5, 2022

Meridian Bioscience Is Not Your Average Life Science Company

100% technical buy signals. 8 new highs and up 15.79% in the last month.

By PRNewsWire
May 23, 2022

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and lif

By Benzinga
May 6, 2022

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segmen

By Seeking Alpha
May 6, 2022

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript

Meridian Bioscience, Inc. (NASDAQ:VIVO ) Q2 2022 Earnings Conference Call May 6, 2022 10:00 AM ET Corporate Participants Charlie Wood - Vice President

By Zacks Investment Research
May 5, 2022

Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable

Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound s

By Zacks Investment Research
April 29, 2022

Meridian Bioscience (VIVO) Expected to Beat Earnings Estimates: Should You Buy?

Meridian Bioscience (VIVO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.